What are Combination chemotherapy drugs?

Combination chemotherapy drugs are pharmacologic agents that share a common mechanism (typically targeting DNA (platinum agents); Topoisomerase II (etoposide)). 0 are currently marketed, with 5 more in clinical development.

Combination chemotherapy

0 marketed 5 in Phase 3

This page covers all Combination chemotherapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA (platinum agents); Topoisomerase II (etoposide).

Targets

DNA (platinum agents); Topoisomerase II (etoposide)

Phase 3 pipeline (5)

Cisplatin/carboplatin plus etoposide · EpicentRx, Inc. · Oncology
This combination uses platinum-based chemotherapy agents (cisplatin or carboplatin) to cross-link DNA, combined with etoposide, a topoisomerase II inhibitor that prevents DNA unwinding and repair.
Gemcitabine plus TS-1 · Taiho Pharmaceutical Co., Ltd. · Oncology
Gemcitabine plus TS-1 is a combination chemotherapy regimen that inhibits DNA synthesis and disrupts nucleotide metabolism to kill rapidly dividing cancer cells.
P-Gemox · The First Affiliated Hospital with Nanjing Medical University · Oncology
P-Gemox is a combination chemotherapy regimen that combines gemcitabine and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
Etoposide-Cisplatin combined chemotherapy · Sumitomo Pharma (Suzhou) Co., Ltd. · Oncology
Etoposide and cisplatin work together as a combination chemotherapy regimen that kills cancer cells by damaging DNA through different mechanisms.
Course A2 + Vin · Children's Cancer Group, China · Oncology
Course A2 + Vin is a combination chemotherapy regimen that uses doxorubicin and vincristine to inhibit cancer cell division and induce apoptosis in pediatric malignancies.